News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fosun Pharma Sells Ex-China Rights for Two Drug Candidates in $531 Million Deal


10/22/2013 6:22:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

October 21, 2013 -- In a blockbuster deal, Shanghai Fosun Pharma plans to sell ex-China rights for two drug candidates – one treating cancer, the other diabetes – to Sellas Clinicals Holding of Switzerland. Sellas will pay up to $531.4 million in clinical milestones, based on trials in the US and Europe. The agreement, which has not been finalized, will be between an indirect subsidiary of Fosun, Chongqing Fochon Pharma, and Sellas. More details....

Stock Symbol: (SHA: 600196; HK: 02196)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today
Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES